This phase I trial tests the safety, side effects, and best dose of combination therapy with liposomal doxorubicin and peposertib in treating patients with sar…

Metastatic Dedifferentiated LiposarcomaMetastatic LeiomyosarcomaMetastatic Myxofibrosarcoma+9 more

~Estimated

~$10 – $5,625

National Cancer Institute (NCI)NCT05711615

Phase 2

A Non-Randomized, Open-label Phase II Trial Testing the Activity of XL092 (Zanzalintinib) in Patients With Advanced Leiomyosarcoma, Bone Sarcoma or Translocation-associated Soft Tissue Sarcoma

This phase II trial tests how well zanzalintinib (XL092) works in treating patients with leiomyosarcoma that has spread from where it first started to other pl…

Metastatic LeiomyosarcomaUnresectable LeiomyosarcomaBone Sarcoma+7 more

~Estimated

~$10 – $6,250

Northwestern UniversityNCT06571734